Incidence of Hypertension During Induction Therapy in Children with Acute Lymphoblastic Leukemia
Indian Pediatrics · 2026
DOI: 10.1007/s13312-025-00206-2 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Indian Pediatrics, 2026. Verfasst von Yamini Karanam und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology-Oncology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, C…. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hypertension, Induction Chemotherapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 25 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
OBJECTIVE: To estimate the incidence of hypertension during induction therapy in children with acute lymphoblastic leukemia (ALL), comparing a systematically monitored prospective cohort to a retrospective cohort lacking regular blood pressure monitoring. METHODS: This ambispective observational study was conducted at a pediatric hematology-oncology unit in Chandigarh, India. The prospective cohort included 46 children with B-/T-ALL or T-cell non-Hodgkin lymphoma enrolled between September 2023 and August 2024, whose blood pressure was monitored weekly during induction therapy using the auscultatory method with an aneroid sphygmomanometer. Hypertension was defined according to the 2017 American Academy of Pediatrics guidelines. The retrospective cohort comprised 160 children diagnosed between June 2022 and July 2023, whose case files were reviewed for documented hypertension or posterior reversible encephalopathy syndrome (PRES). In the retrospective cohort, blood pressure was not monitored systematically and was detected incidentally during routine care or at the time of admission for intercurrent illnesses. RESULTS: Hypertension was observed in 27 (58.7%) patients in the prospective cohort, compared to 20 (12.5%) in the retrospective (P < 0.001). Most (92.6%) cases of hypertension in the prospective cohort occurred within the first two weeks of induction. No case vs. two (1.3%) cases of PRES were reported in the prospective and retrospective cohorts. CONCLUSION: The incidence of hypertension during induction therapy in childhood ALL was 58.7%, with most cases occurring within the first two weeks. Incorporating blood pressure monitoring into routine care is essential for children with ALL receiving induction chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India. deepakbansaldr@gmail.com.
ORCID-Profile: Deepak Bansal
Zitieren
APA
Karanam, Y., Trehan, A., & Bansal, D. (2026). Incidence of Hypertension During Induction Therapy in Children with Acute Lymphoblastic Leukemia. Indian Pediatrics. https://doi.org/10.1007/s13312-025-00206-2
Vancouver
Karanam Y, Trehan A, Bansal D. Incidence of Hypertension During Induction Therapy in Children with Acute Lymphoblastic Leukemia. Indian Pediatrics. 2026. doi:10.1007/s13312-025-00206-2
BibTeX
@article{Karanam2026,
author = {Karanam, Yamini and Trehan, Amita and Bansal, Deepak},
title = {Incidence of Hypertension During Induction Therapy in Children with Acute Lymphoblastic Leukemia},
journal = {Indian Pediatrics},
year = {2026},
doi = {10.1007/s13312-025-00206-2}
}
EUVIMED